CERO THERAPEUTICS HOLDINGS I (CERO) Stock News

USA - NASDAQ:CERO - US71902K4022 - Common Stock

2.6 USD

-0.25 (-8.61%)

Last: 10/15/2025, 8:19:08 PM

2.69 USD

+0.09 (+3.46%)

Pre-Market: 10/16/2025, 8:20:01 AM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

CERO Latest News, Press Relases and Analysis

All

Press Releases

a day ago - By: CERo Therapeutics Holdings, Inc.

CERo Therapeutics to Participate in Stem Cell Therapy Panel at the Maxim Growth Summit 2025

a day ago - By: CERo Therapeutics Holdings, Inc.

CERo Therapeutics to Participate in Stem Cell Therapy Panel at the Maxim Growth Summit 2025

3 days ago - By: CERo Therapeutics Holdings, Inc.

CERo Therapeutics Announces Completion of First Cohort of Phase 1 Clinical Trial of CER-1236 in AML

3 days ago - By: CERo Therapeutics Holdings, Inc.

CERo Therapeutics Announces Completion of First Cohort of Phase 1 Clinical Trial of CER-1236 in AML

a month ago - By: Benzinga - Mentions: SMMT RENB

Top 3 Health Care Stocks You'll Regret Missing In Q3

a month ago - By: Stocktwits

News Image

CERo Therapeutics Gets Fast Track Designation For Experimental Cancer Drug, But Stock Tumbles – Here’s What Happened

4 months ago - By: Benzinga - Mentions: SEDG RUN PCSA ACXP ...

US Stocks Lower; Retail Sales Decline In May

24 days ago - By: CERo Therapeutics Holdings, Inc.

CERo Therapeutics Progresses Phase 1 CER-1236 AML Trial with Dosing of Third Patient in Initial Dose Cohort

24 days ago - By: CERo Therapeutics Holdings, Inc.

CERo Therapeutics Progresses Phase 1 CER-1236 AML Trial with Dosing of Third Patient in Initial Dose Cohort

a month ago - By: CERo Therapeutics Holdings, Inc.

CERo Therapeutics Receives Notice of Allowance from U.S. Patent and Trade Office on Composition of Matter and Method of Use for CER-1236 in Cancer with Expected Protection Through 2041

a month ago - By: CERo Therapeutics Holdings, Inc.

CERo Therapeutics Receives Notice of Allowance from U.S. Patent and Trade Office on Composition of Matter and Method of Use for CER-1236 in Cancer with Expected Protection Through 2041

a month ago - By: CERo Therapeutics Holdings, Inc.

CERo Therapeutics Announces Dose Intensification in Phase 1 Study of CER-1236 in Acute Myeloid Leukemia

a month ago - By: CERo Therapeutics Holdings, Inc.

CERo Therapeutics Announces Dose Intensification in Phase 1 Study of CER-1236 in Acute Myeloid Leukemia

a month ago - By: CERo Therapeutics Holdings, Inc.

CERo Therapeutics Receives FDA Fast Track Designation for CER-1236 in Acute Myeloid Leukemia (AML)

a month ago - By: CERo Therapeutics Holdings, Inc.

CERo Therapeutics Receives FDA Fast Track Designation for CER-1236 in Acute Myeloid Leukemia (AML)

3 months ago - By: CERo Therapeutics Holdings, Inc.

CERo Therapeutics Doses Second Acute Myeloid Leukemia Patient with CER-1236

3 months ago - By: CERo Therapeutics Holdings, Inc.

CERo Therapeutics Doses Second Acute Myeloid Leukemia Patient with CER-1236

4 months ago - By: CERo Therapeutics Holdings, Inc.

CERo Therapeutics Holdings, Inc. Announces First Patient Completes Dose-Limiting Toxicity Observation Period with No Reported DLTs in Phase 1 Trial of CER-1236

4 months ago - By: CERo Therapeutics Holdings, Inc.

CERo Therapeutics Holdings, Inc. Announces First Patient Completes Dose-Limiting Toxicity Observation Period with No Reported DLTs in Phase 1 Trial of CER-1236

4 months ago - By: Stocktwits

Cero Therapeutics Rockets On FDA Orphan Drug Status For Blood Cancer Drug; Retail Bulls Feel Stock 'Still Has A Few Pumps Left'